Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12535945 | 0.90 | SIGMAR1 (0.74) | MAOASIGMAR1MC4RPOLBDRD4 | |
| SCHEMBL1639608 | 0.85 | SIGMAR1 (0.65) | MAOASIGMAR1MC4RPOLBDRD4 | |
| SCHEMBL12259888 | 0.83 | SIGMAR1 (0.53) | MAOASIGMAR1MC4RPOLBDRD4 | |
| SCHEMBL21812111 | 0.82 | SIGMAR1 (0.57) | MAOASIGMAR1MC4RPOLBDRD4 | |
| SCHEMBL159371 | 0.82 | SIGMAR1 (0.61) | MAOASIGMAR1MC4RPOLBDRD4 | |
| SCHEMBL8544175 | 0.81 | MAOA (1.00) | MAOASIGMAR1ACHE | |
| SCHEMBL10733638 | 0.81 | MAOA (0.47) | MAOADRD4ACHEBCHEBACE1 | |
| SCHEMBL7231784 | 0.81 | ALDH1A1 (0.56) | MAOASIGMAR1LMNAALDH1A1 | |
| SCHEMBL10729859 | 0.81 | ALDH1A1 (0.55) | MAOAPOLBLMNAACHEALDH1A1 | |
| SCHEMBL4591437 | 0.81 | ALDH1A1 (0.53) | MAOAPOLBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4645771-A | ANTICOAGULANT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-02-24 | — | — | US | claimed |
| EP-0004727-B1 | BLOOD PLATELET AGGREGATION INHIBITORY PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESSES FOR THEIR MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-12 | — | — | EP | claimed |
| EP-0004727-A2 | Blood platelet aggregation inhibitory pyridine derivatives, pharmaceutical compositions thereof, and processes for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-10-17 | — | — | EP | claimed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| CN-115087638-B | PRMT5 inhibitors | 默沙东公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230349869-A1 | METHODS AND SYSTEMS FOR OPIOID DETECTION | NAT TECH & ENG SOLUTIONS SANDIA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11733217-B1 | Methods and systems for opioid detection | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230108114-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | US | disclosed |
| EP-0163238-A2 | Substituted and bridged pyridines useful as pharmaceutical agents | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | disclosed |
| EP-0004727-B1 | BLOOD PLATELET AGGREGATION INHIBITORY PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESSES FOR THEIR MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-12 | — | — | EP | disclosed |
| US-4267183-A | Tetrahydropyridine derivative | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-05-12 | — | — | US | disclosed |
| EP-0004726-B1 | BLOOD PLATELET AGGREGATION INHIBITORY TETRAHYDROPYRIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND PROCESSES FOR ITS MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-01-28 | — | — | EP | disclosed |
| US-4238488-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-12-09 | — | — | US | disclosed |
| US-4225602-A | Tetrahydropyridine derivative useful for inhibiting blood platelet aggregation | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-09-30 | — | — | US | disclosed |
| EP-0004727-A2 | Blood platelet aggregation inhibitory pyridine derivatives, pharmaceutical compositions thereof, and processes for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-10-17 | — | — | EP | disclosed |
| EP-0004727-A2 | Blood platelet aggregation inhibitory pyridine derivatives, pharmaceutical compositions thereof, and processes for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-10-17 | — | — | EP | disclosed |
| EP-0004726-A1 | Blood platelet aggregation inhibitory tetrahydropyridine derivative, pharmaceutical compositions thereof and processes for its manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | MAOA 4536/4885SIGMAR1 918/4885MC4R 4020/4885 |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | MAOA 4656/4885SIGMAR1 3822/4885MC4R 3283/4885 |
| US-12595262-B2 | PRMT5 inhibitors | PRMT1, PRMT5, CARM1 | MAOA 4799/4885SIGMAR1 1286/4885MC4R 3389/4885 |
| US-20230108114-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | MAOA 4350/4885SIGMAR1 3301/4885MC4R 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.